ClinicalTrials.Veeva

Menu

Bacteriological Evaluation of Children With Otorrhea

A

Association Clinique Thérapeutique Infantile du val de Marne

Status

Enrolling

Conditions

Otorrhea

Treatments

Other: middle ear fluid sample

Study type

Observational

Funder types

Other

Identifiers

NCT04807660
ACT0315

Details and patient eligibility

About

After pneumococcal conjugate vaccine implementation, the number of acute otitis media (AOM) episodes has decreased, but AOM still remains among the most common diagnoses in childhood. From 2% to 17% of cases of AOM feature spontaneous perforation of the tympanic membrane (SPTM). The aim of this study was to describe the bacteriological causes of SPTM several years after PCV13 implementation, in 2010.

Full description

Since October 2015, children with spontaneous perforation of the tympanic membrane (SPTM) are prospectively enrolled by 41 pediatricians who are part of a research and teaching network (ACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne [Clinical and Therapeutic Association of Val de Marne]) throughout France. For some patients, otorrhea is the first manifestation of AOM; for others, otorrhea occurred after AOM treatment failure or recurrence. Failure (non-responsive AOM) is defined as otorrhea appearing despite at least 48 hr of antibiotics or recurring less than 4 days after the end of antibiotic treatment. Recurrence is defined by the appearance of otorrhea 4 to 30 days after the end of antibiotic treatment for AOM.

Middle ear fluid (MEF) is obtained by sampling spontaneous discharge according to clinical practice guidelines. MEF specimens are obtained with cotton-tipped wire swabs, immediately placed in transport medium (Copan Venturi Transystem®, Brescia, Italy), and transported within 48 hr to one of the two centralized microbiology laboratories (Robert Debré Hospital or National Centre for Pneumococci at European Georges Pompidou Hospital, Paris, France).

Enrollment

1,500 estimated patients

Sex

All

Ages

3 months to 15 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • children from 3 months to 15 years old
  • with otorrhea
  • signed parents consent

Exclusion criteria

  • children under 3 months
  • children > 15 years old

Trial design

1,500 participants in 1 patient group

Prospective cohort
Description:
Middle ear fluid sample for each enrrolled children
Treatment:
Other: middle ear fluid sample

Trial contacts and locations

1

Loading...

Central trial contact

Stéphane Béchet, MSc; Corinne Levy, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems